Brii Biosciences Limited (7SS) Ratios
Brii Biosciences Limited Ratios
DE:7SS's free cash flow for Q2 2026 was $-141.55M. For the 2026 fiscal year, DE:7SS's free cash flow was decreased by $-9.60M and operating cash flow was $-131.94M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 60.73 | 31.18 | 22.11 | 13.43 | 12.16 |
| Quick Ratio | 60.73 | 31.18 | 22.11 | 13.43 | 12.16 |
| Cash Ratio | 18.83 | 12.96 | 3.89 | 5.20 | 10.17 |
| Solvency Ratio | -5.83 | -4.98 | -1.26 | -2.03 | -13.69 |
| Operating Cash Flow Ratio | -8.86 | -4.82 | -4.72 | -2.17 | -3.13 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 1.93B | $ 2.31B | $ 2.66B | $ 2.84B | $ 3.11B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 |
| Debt-to-Equity Ratio | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 |
| Debt-to-Capital Ratio | 0.00 | 0.01 | 0.00 | 0.00 | 0.01 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 0.99 | 1.02 | 1.03 | 1.06 | 1.08 |
| Debt Service Coverage Ratio | -152.93 | 0.00 | -340.49 | -548.10 | -452.72 |
| Interest Coverage Ratio | -154.89 | 0.00 | -1101.82 | -603.81 | -519.55 |
| Debt to Market Cap | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.02 | 0.04 | 0.01 | 0.02 | 0.05 |
| Net Debt to EBITDA | 2.07 | 2.48 | 2.89 | 2.34 | 4.70 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| EBIT Margin | -1632.59% | -735.92% | -326.47% | -995.32% | -659.68% |
| EBITDA Margin | -1601.74% | -723.05% | -298.64% | -975.45% | -651.38% |
| Operating Profit Margin | -1632.59% | -735.92% | -966.41% | -995.32% | -659.68% |
| Pretax Profit Margin | -1194.13% | -943.85% | -327.35% | -948.71% | -4528.85% |
| Net Profit Margin | -1196.58% | -936.08% | -310.41% | -938.12% | -4452.28% |
| Continuous Operations Profit Margin | -1204.34% | -943.85% | -327.35% | -948.71% | -4528.85% |
| Net Income Per EBT | 100.21% | 99.18% | 94.83% | 98.88% | 98.31% |
| EBT Per EBIT | 73.14% | 128.25% | 33.87% | 95.32% | 686.53% |
| Return on Assets (ROA) | -9.19% | -18.77% | -5.47% | -14.28% | -114.08% |
| Return on Equity (ROE) | -9.12% | -19.13% | -5.61% | -15.16% | -123.25% |
| Return on Capital Employed (ROCE) | -12.71% | -15.19% | -17.72% | -16.25% | -18.33% |
| Return on Invested Capital (ROIC) | -12.68% | -15.17% | -17.70% | -14.97% | -17.97% |
| Return on Tangible Assets | -10.51% | -20.11% | -5.97% | -14.93% | -114.38% |
| Earnings Yield | -23.72% | -75.60% | -11.73% | -10.29% | -34.87% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 3.22 | 4.47 | 15.48 |
| Payables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 1.28 | 3.80 | 10.04 | 2.64 | 2.77 |
| Asset Turnover | 0.01 | 0.02 | 0.02 | 0.02 | 0.03 |
| Working Capital Turnover Ratio | 0.01 | 0.02 | 0.02 | 0.02 | 0.05 |
| Cash Conversion Cycle | 0.00 | 0.00 | 113.30 | 81.66 | 23.59 |
| Days of Sales Outstanding | 0.00 | 0.00 | 113.30 | 81.66 | 23.59 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 0.00 | 0.00 | 113.30 | 81.66 | 23.59 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.40 | -0.51 | -0.82 | -0.69 | -2.00 |
| Free Cash Flow Per Share | -0.40 | -0.52 | -0.88 | -0.88 | -2.01 |
| Dividend Paid and CapEx Coverage Ratio | -153.61 | -115.52 | -11.97 | -3.56 | -854.67 |
| Capital Expenditure Coverage Ratio | -153.61 | -115.52 | -11.97 | -3.56 | -854.67 |
| Operating Cash Flow Coverage Ratio | -32.08 | -13.31 | -188.22 | -39.21 | -40.69 |
| Operating Cash Flow to Sales Ratio | -15.81 | -6.87 | -10.55 | -9.61 | -9.50 |
| Free Cash Flow Yield | -31.55% | -55.96% | -43.17% | -13.50% | -7.45% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -4.22 | -1.32 | -8.53 | -9.72 | -2.87 |
| Price-to-Sales (P/S) Ratio | 50.44 | 12.38 | 26.47 | 91.20 | 127.70 |
| Price-to-Book (P/B) Ratio | 0.38 | 0.25 | 0.48 | 1.47 | 3.54 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -3.17 | -1.79 | -2.32 | -7.41 | -13.42 |
| Price-to-Operating Cash Flow Ratio | -3.19 | -1.80 | -2.51 | -9.49 | -13.44 |
| Price-to-Earnings Growth (PEG) Ratio | 0.07 | -0.01 | 0.13 | 0.10 | -0.01 |
| Enterprise Value Multiple | -1.08 | 0.77 | -5.97 | -7.01 | -14.90 |
| Enterprise Value | 314.52M | -303.21M | 1.00B | 3.53B | 8.98B |
| EV to EBITDA | -1.08 | 0.77 | -5.97 | -7.01 | -14.90 |
| EV to Sales | 17.35 | -5.59 | 17.84 | 68.38 | 97.08 |
| EV to Free Cash Flow | -1.09 | 0.81 | -1.56 | -5.55 | -10.20 |
| EV to Operating Cash Flow | -1.10 | 0.81 | -1.69 | -7.11 | -10.22 |
| Tangible Book Value Per Share | 2.81 | 3.32 | 3.85 | 4.16 | 7.52 |
| Shareholders’ Equity Per Share | 3.29 | 3.64 | 4.28 | 4.42 | 7.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.01 | 0.00 | 0.00 | 0.08 | 0.02 |
| Revenue Per Share | 0.03 | 0.07 | 0.08 | 0.07 | 0.21 |
| Net Income Per Share | -0.30 | -0.70 | -0.24 | -0.67 | -9.38 |
| Tax Burden | 1.00 | 0.99 | 0.95 | 0.99 | 0.98 |
| Interest Burden | 0.73 | 1.28 | 1.00 | 0.95 | 6.87 |
| Research & Development to Revenue | 11.41 | 4.60 | 7.15 | 8.54 | 5.34 |
| SG&A to Revenue | 5.61 | 3.76 | 0.99 | 1.04 | 0.86 |
| Stock-Based Compensation to Revenue | 0.36 | 0.30 | 1.14 | 1.51 | 0.86 |
| Income Quality | 1.29 | 0.73 | 3.22 | 1.01 | 0.21 |
Currency in CNY